LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates GlobeNewswire January 07, 2026 Launched VIZZ(TM) (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025 […]